Home > Boards > US Listed > Medical - Drugs >

Precipio Inc. (PRPO)

Add PRPO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/17/2018 1:34:45 AM - Followers: 77 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).



New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437
E-mail: investorrelations@transgenomic.com

SEC Filings:

Press Releases:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1990   This is a bad news with RS skwong 11/17/18 01:34:44 AM
#1989   PRE 14A proxy.... mgland 11/16/18 09:58:44 AM
#1988   Precipio CEO Sends Letter To Shareholders Related To mgland 11/16/18 09:55:26 AM
#1987   Good news in PRPO NT 10-Q aries4747 11/14/18 05:57:50 PM
#1986   i may add here in the morning take saigai 11/14/18 12:20:48 AM
#1985   I have 150K so a significant stake in PennyStockTrader2 11/13/18 05:04:11 PM
#1984   i only have 30k shares and hoping to saigai 11/13/18 04:57:33 PM
#1983   PRPO 10Q and CC due soon. aries4747 11/13/18 03:22:23 PM
#1982   PRPO setting up for sweet close. aries4747 11/13/18 03:16:52 PM
#1981   I would start to sell at maybe .45 PennyStockTrader2 11/13/18 03:02:46 PM
#1980   chewing up the over hang nicely.. this is saigai 11/13/18 12:10:54 PM
#1979   this is so due for a bounce into PennyStockTrader2 11/13/18 09:45:03 AM
#1978   Nice day here. I Need Money 11/01/18 02:23:36 PM
#1977   Don't worry, IT will not!!!!!!! Dean The Great 10/23/18 10:14:49 PM
#1976   Don't let the door hit ya in the ass! laser777 10/23/18 01:56:06 PM
#1975   Precipio management sucks! Run!! Dean The Great 10/23/18 12:06:19 PM
#1974   I agreed with you and thought about loading chuckt880 10/22/18 02:16:51 PM
#1973   Picked up 38K shares this morning, this is PennyStockTrader2 10/22/18 11:10:15 AM
#1972   Nice news today. back in @ .345 mgland 10/16/18 03:22:01 PM
#1971   PRPO 35%% going now,huge revenue m1999 10/16/18 08:08:23 AM
#1970   The prospectus from 10/1? perhaps mgland 10/09/18 12:02:00 PM
#1969   Getting tempting here again mgland 10/09/18 11:59:03 AM
#1968   Just trying to always maximize profits. For instance, PennyStockTrader2 10/03/18 05:31:37 PM
#1967   Are you a money-hungry person? pietro13 10/03/18 05:27:14 PM
#1966   Took some off the table in the pre-market PennyStockTrader2 10/03/18 05:03:03 PM
#1965   Great news today. willlbone 10/03/18 08:21:52 AM
#1964   More info from 9/14 Form S-1 aries4747 09/20/18 11:03:23 AM
#1963   Flipped a couple on this mornings spike. Was mgland 09/20/18 10:21:24 AM
#1962   Waiting to see if they're granted extension. aries4747 09/20/18 10:16:11 AM
#1961   Back in with a starter. mgland 09/18/18 10:02:02 AM
#1960   Here's the problem. Addressing the issues doesn't mean SidVicious 08/23/18 07:50:12 PM
#1959   From today's PRPO CC aries4747 08/23/18 12:15:58 PM
#1958   Would you care to elaborate on this statement? laser777 08/23/18 11:51:22 AM
#1957   Good buyers opportunity today. Expect big things next week. Penny pinching 08/23/18 11:18:57 AM
#1956   PRPO files 10Q. aries4747 08/16/18 05:51:27 PM
#1955   https://ih.advfn.com/p.php?pid=nmona&article=78041619 beambe 08/09/18 12:12:55 PM
#1954   VolumeOMG beambe 08/08/18 05:25:00 PM
#1953   Revenues are increasing and growing acceptance in the awaitingamove 08/02/18 01:24:05 AM
#1952   Why would this go to $1 laplova 08/01/18 06:57:46 PM
#1951   https://www.nasdaq.com/symbol/prpo/after-hours beambe 08/01/18 04:20:37 PM
#1950   OMG-Volume NEWS ? beambe 08/01/18 04:17:41 PM
#1949   Patience beambe 08/01/18 03:48:55 PM
#1948   PRPO (.47): Late day pps and volume boom. aries4747 08/01/18 03:42:43 PM
#1947   It will go to $1 tomorrow as the SidVicious 07/26/18 11:13:12 PM
#1946   Will it be sell off in the morning RavenEyesStocks 07/26/18 04:17:36 PM
#1945   Thanks. I’m with ya. Hopefully good things are coming. rightothesky 07/25/18 07:40:03 AM
#1944   thats a solid price. I have 110K+ shares PennyStockTrader2 07/25/18 06:09:06 AM
#1943   I got about 20k shares of this @ rightothesky 07/24/18 10:55:38 PM
#1942   Took about 10% off the table on that PennyStockTrader2 07/24/18 07:28:23 PM
#1941   Yeah, that you’ll be wrong SidVicious 07/22/18 11:40:25 PM